Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EBMT 2020 | LY.12 & CORAL: long-term survival in relapsed DLBCL after ASCT

Christian Gisselbrecht • 31 Aug 2020
EBMT 2020
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Cisplatin Cytarabine Rituximab
CORAL LY.12

Christian Gisselbrecht, MD, Saint-Louis Hospital, Paris, France, discusses long-term survival after 2 year’s event-free survival in relapsed diffuse large B-cell lymphoma (DLBCL) after autologous stem cell transplantation (ASCT) in the two randomized trials LY.12 (NCT00078949) and CORAL (NCT00137995). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Christian Gisselbrecht

Selecting between autoSCT & CAR-T in DLBCL: patient selection, drug access, and long-term efficacy
2:25
Selecting between autoSCT & CAR-T in DLBCL: patient selection, drug access, and long-term efficacy
Christian Gisselbrecht • 25 Apr 2023
Promising advances in the field of PTCL: druggable mutations, brentuximab vedotin & L-asparaginase
2:15
Promising advances in the field of PTCL: druggable mutations, brentuximab vedotin & L-asparaginase
Christian Gisselbrecht • 25 Apr 2023
The current status of autologous transplantation in PTCL
1:15
The current status of autologous transplantation in PTCL
Christian Gisselbrecht • 25 Apr 2023
ZUMA-1 & SCHOLAR-1: comparison of outcomes in refractory DLBCL
2:38
ZUMA-1 & SCHOLAR-1: comparison of outcomes in refractory DLBCL
Christian Gisselbrecht • 31 Aug 2020

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Christian Gisselbrecht • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Christian Gisselbrecht • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Christian Gisselbrecht • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Christian Gisselbrecht • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals